Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 12/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13013339 | 0.85 | NR4A2 (0.74) | NR4A2CREBBPGPR84IDO1 | |
| SCHEMBL3995062 | 0.84 | NR4A2 (0.72) | NR4A2CREBBPGPR84IDO1 | |
| SCHEMBL21438856 | 0.83 | NR4A2 (0.70) | NR4A2CREBBPGPR84RAB9ASMN1; SMN2 | |
| SCHEMBL9937305 | 0.83 | NR4A2 (0.70) | NR4A2CREBBPGPR84MAP2K1RAB9A | |
| SCHEMBL5329797 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPRAB9A | |
| SCHEMBL26250363 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1RAB9A | |
| SCHEMBL2035795 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPGPR84MAP2K1 | |
| SCHEMBL3554889 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1RAB9A | |
| SCHEMBL3996872 | 0.80 | NR4A2 (0.67) | NR4A2GPR84 | |
| SCHEMBL21037791 | 0.79 | NR4A2 (0.65) | NR4A2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110191882-B | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 株式会社大熊制药 | 2022-09-13 | — | — | CN | disclosed |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-20 | — | — | US | disclosed |
| WO-2018147626-A1 | NOVEL HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-08-16 | — | — | WO | disclosed |
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| CN-103347874-A | Dimeric iap inhibitors | NOVARTIS AG | 2013-10-09 | — | — | CN | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | NR4A2 3995/4885CREBBP 3960/4885GPR84 3715/4885 |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | RNASE1, AARS1, DHPS | NR4A2 4274/4885CREBBP 483/4885GPR84 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.